The story
In 1957 two drugs were reported to lift severe depression. In the United States, the psychiatrist Nathan Kline described the effects of iproniazid, a drug developed to treat tuberculosis. Doctors at a New York sanatorium had noticed in 1952 that patients taking it became unusually cheerful and active. In Switzerland, the psychiatrist Roland Kuhn, working with the company Geigy at a hospital in Münsterlingen, reported that imipramine relieved depression. Geigy had developed imipramine as a possible treatment for schizophrenia, a field opened up by chlorpromazine in the early 1950s, and it failed at that, but Kuhn saw it help depressed patients.
The new drugs fell into two classes, monoamine oxidase inhibitors, or MAOIs, such as iproniazid, and tricyclics, such as imipramine, and both seemed to raise levels of brain chemicals such as serotonin and norepinephrine, which led to the monoamine theory of depression. Iproniazid was withdrawn in 1961 over liver toxicity, and MAOIs were later found to react dangerously with certain foods, including aged cheese. Prozac, approved in the United States in December 1987, became the most famous of the SSRIs, which target serotonin more specifically, and antidepressants became among the most widely prescribed medicines in the world.
Why it mattered
- The drugs showed depression could be treated with medication and gave the first evidence that mood disorders had a chemical basis.
- They guided the monoamine theory of depression and decades of drug development, leading to SSRIs such as Prozac.
- They moved much of mental health care out of psychiatric hospitals and into outpatient clinics.
- They raised lasting debates about overprescription, side effects and how well antidepressants work compared with placebos.
Sources
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…